Companies

Companies are core nodes in the Weight Loss Index database. They connect drug portfolios, active ingredients, clinical programs, regulatory milestones, manufacturing context, partnerships, acquisitions, commercialization relationships, and treatment channels.

This area is intended for pharmaceutical companies, biotechnology companies, manufacturers, commercial partners, and other organizations whose activities materially shape the obesity treatment market. Company records should emphasize sourced industry relationships rather than promotional descriptions or generic corporate summaries.

As the database grows, company pages should help readers understand what each organization develops, markets, supplies, licenses, acquires, or commercializes, and how those activities connect to related drugs, ingredients, mechanisms, clinical programs, and regulatory events.

This is a starting company-level map for US obesity-treatment products, not an ownership database, access guide, investment view, or product recommendation surface. Company and commercialization details can change over time, so product ownership, distribution, licensing, manufacturer, shortage, pricing, and reimbursement records should be treated as dated and source-specific when individual company pages are added.

The most recent source context reviewed for this hub is July 23, 2026. For fast-changing matters, prefer the linked FDA, DailyMed, company, or trial-registry records over unsourced summaries.

Manufacturer and commercial partner records

Weight loss drug manufacturer and commercial partner records separate company roles that are often collapsed in ordinary use. A product-related company may be a developer, regulatory sponsor, approval holder, labeler, physical manufacturer, distributor, commercialization partner, or current corporate owner. Those roles can differ by product, jurisdiction, and date.

This distinction matters for products such as Wegovy, Zepbound, Saxenda, Qsymia, Contrave, Xenical, and Alli because a single company name does not necessarily answer every ownership, manufacturing, supply, label, or market-access question.

Novo Nordisk

Novo Nordisk is one of the anchor companies in the modern obesity-treatment market. Its full company record connects Wegovy, Saxenda, semaglutide, liraglutide, GLP-1 and amylin programs, manufacturing and supply, corporate ownership, and regulatory events.

Product and regulatory context

Wegovy is the most important Novo Nordisk obesity product for this hub because it links weight reduction, semaglutide, GLP-1 manufacturing capacity, and adjacent cardiometabolic label expansion. In March 2024, FDA approved a Wegovy indication to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. That regulatory milestone makes Novo Nordisk relevant not only as an obesity-drug sponsor, but also as a company shaping how obesity medicines are positioned in cardiovascular-risk and payer-policy discussions.

Saxenda keeps Novo Nordisk connected to the earlier liraglutide era of GLP-1 obesity treatment. It is useful as a historical and comparison record because it shows how a company with diabetes-origin incretin products moved from diabetes care into chronic weight management before the semaglutide market expanded.

Pipeline and market interpretation

Novo Nordisk’s near-term obesity strategy also includes development-stage assets and combinations. The company submitted CagriSema, a cagrilintide/semaglutide fixed-dose combination, for FDA review in December 2025 and reported that its zenagamtide obesity phase 3 program began in the first quarter of 2026. Those records remain separate from approved products unless a regulator grants market authorization.

Source context: Novo Nordisk company record, 2025 annual report, first-quarter 2026 results, current DailyMed Wegovy label

Eli Lilly

Eli Lilly is the other major anchor company in the current incretin-based obesity market. Its full company record connects tirzepatide, Zepbound, Mounjaro, Foundayo, GIP/GLP-1 receptor agonists, late-stage obesity development, manufacturing scale, and direct commercial channels.

Product and regulatory context

Zepbound is Lilly’s central injectable obesity product in this company map. FDA approved it for long-term weight reduction and maintenance in a defined adult population in November 2023. The FDA notice also makes the company-product connection explicit by granting the approval to Eli Lilly and Co.

Lilly’s obesity footprint widened again in December 2024, when FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, to be used with a reduced-calorie diet and increased physical activity. That approval matters for industry mapping because it links an obesity medicine to a sleep-medicine indication and to clinical endpoints beyond body-weight reduction alone.

Mounjaro should be kept distinct from Zepbound in company records even though both connect to tirzepatide. Mounjaro is the related diabetes product, while Zepbound is the obesity and obesity-related OSA product. That distinction helps prevent ingredient-level summaries from flattening diabetes, obesity, and adjacent cardiometabolic indications into one undifferentiated commercial category.

Pipeline and market interpretation

FDA approved Lilly’s oral GLP-1 product Foundayo, containing orforglipron, on April 1, 2026. Retatrutide remains investigational and in phase 3 development as of July 23, 2026. Keeping the two records separate prevents an approved oral product and a development-stage triple-receptor asset from being grouped under one generic pipeline label.

Source context: Eli Lilly company record, current DailyMed Zepbound label, FDA Foundayo approval notice, April 1, 2026, ClinicalTrials.gov TRIUMPH-1 record

VIVUS-related Qsymia records

VIVUS-related records connect the company database to Qsymia, the phentermine/topiramate extended-release product in the US chronic weight-management market. Qsymia is important because it represents an oral fixed-dose combination category that predates the current incretin-centered market and remains mechanistically distinct from GLP-1 or GIP/GLP-1 products.

Product relationship

Qsymia gives the database a way to compare older oral chronic weight-management products with newer incretin products without implying that the products are clinically interchangeable. Company-level records should connect Qsymia to phentermine/topiramate, the sympathomimetic/antiepileptic combination class, FDA label history, risk-management context, and any dated corporate events that affect how the product is marketed or supplied.

Ownership and label caution

For industry research, the Qsymia company relationship is most useful when it separates development history, approval-holder or labeler information, commercial availability, and current corporate structure. VIVUS is historically associated with the product, but company names, labeler records, and commercialization arrangements should be checked against dated label and corporate sources before being reused as current ownership claims.

Source context: DailyMed Qsymia label search

Contrave-related company records

Contrave-related records connect the company database to naltrexone/bupropion extended-release and to a commercialization history that should be handled carefully over time. Contrave is part of the older oral chronic weight-management landscape, outside the incretin and lipase-inhibitor categories.

Product relationship

Contrave remains useful for the Weight Loss Index knowledge graph because it connects product records, naltrexone/bupropion, oral fixed-dose mechanisms, and commercialization pathways that are different from the dominant GLP-1 and GIP/GLP-1 portfolios. That contrast helps readers understand that the obesity-treatment market includes older oral products, newer injectable and oral incretin programs, and products with very different evidence, label, access, and commercial histories.

Commercialization history

The company story around Contrave is more complicated than a single developer-to-product line. Future records should distinguish original development, FDA approval history, label-holder or labeler records, post-approval obligations, current commercial partners, and jurisdiction-specific brand names only when each relationship is supported by a dated source.

Source context: DailyMed Contrave label search

Orlistat-related company records

Orlistat-related records connect the company database to both prescription Xenical and nonprescription Alli. This makes the company context useful for mapping how obesity-related products can move through prescription and over-the-counter channels rather than only through specialist, pharmacy-benefit, or injectable-drug pathways.

Product relationship

Xenical and Alli should be handled as separate product records even though both connect to orlistat and the lipase inhibitor mechanism. Prescription status, nonprescription status, dose, label language, brand ownership, distribution channel, and jurisdiction can differ. Company pages should avoid collapsing those differences into a single generic “orlistat company” claim.

Channel and market interpretation

This section is also useful for industry comparison because orlistat sits outside the incretin race. Its company context points to a different kind of obesity product: a gastrointestinal mechanism, older approval history, mature brand and generic dynamics, and a consumer-health channel for lower-dose nonprescription products. Those features make orlistat records valuable even when the current market conversation is dominated by Novo Nordisk, Eli Lilly, semaglutide, tirzepatide, and next-generation incretin programs.

Source context: DailyMed Xenical label search, DailyMed Alli label search